LexDanaLexDanabeta
Inventor

Miroslav Rapta

Inventor
San Carlos, CA, US

Overview

55→
Patents
2008–2021
Patent span
Human necessities
Primary field (CPC A)

Patents· 55 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations28%
A61KPreparations for medical, dental or toiletry purposes25%
C07DHeterocyclic compounds25%
C07BGeneral methods of organic chemistry9%
C07CAcyclic or carbocyclic compounds8%
C30BSingle-crystal growth3%
Y10TTechnical subjects covered by former us classification2%
PatentTitleYear
11,033,533(2R,4R)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid202110,968,205Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors202110,946,006Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound202110,752,599Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof202010,640,467Process for preparing 2-(1-(tert-butoxycarbonyl)piperidine-4-yl)benzoic acid202010,576,073Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound202010,548,879(2R,4R)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid202010,538,513Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors202010,472,335Crystalline(2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-bipheny]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof201910,426,766Crystalline forms of an 8-azabicyclo[3.2.1]octane compound201910,392,368Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors201910,226,454Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound201910,172,834(2R,4R)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid201910,100,021Crystalline(2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof201810,011,581Process for preparing 4-amino-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-pentanoic acid compound20189,949,963Crystalline forms of an 8-azabicyclo[3.2.1]octane compound20189,872,855(2R,4R)-5-(5'-Chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid20189,868,698'(2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid'20189,676,742'Process for preparing 4-amino-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-pentanoic acid compound'20179,670,143'(2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxmethyl-2-methylpentanoic acid'20179,533,962'(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid'20179,433,598'(2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid'20169,290,491'Crystalline forms of an 8-azabicyclo[3.2.1]octane compound'20169,271,965'Crystalline forms of (R)-3-[N-(3\'-chlorobiphenyl-4-ylmethyl)-N\'-(3-hydroxyisoxazole-5-carbonyl)hydrazino]-2-hydroxyproprionic acid isopropyl ester'20169,187,423'Process for preparing 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds'20159,096,577'Process for preparing 4-amino-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-pentanoic acid compound'20159,073,859'Crystalline form of a 4-[2-(2-fluorophenoxymethyl) phenyl]piperidine compound'20158,969,370'3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists'20158,969,367'Crystalline forms of a 3-carboxypropyl-aminotetralin compound'20158,962,864'Process for preparing 4-amino-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-pentanoic acid compounds'20158,933,111'Crystalline form of (2S,4R)-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-4-[(1H-[1,2,3]triazole-4-carbonyl)-amino]-pentanoic acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester'20158,816,091'Crystalline forms of an 8-azabicyclo[3.2.1]octane compound'20148,802,857'Process for preparing 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds'20148,754,223'Crystalline form of a biphenyl compound'20148,697,724'Crystalline oxalate salts of a diamide compound'20148,592,596'Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound'20138,536,335'Crystalline forms of an 8-azabicyclo[3.2.1]octane compound'20138,492,399'3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists'20138,486,958'Crystalline forms of a 3-carboxypropyl-aminotetralin compound'20138,476,299'Crystalline form of a biphenyl compound'20138,324,236'Crystalline forms of a 3-carboxypropyl-aminotetralin compound'20128,304,433'Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound'20128,247,433'Process for preparing 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds'20128,247,555'Crystalline forms of an 8-azabicyclo[3.2.1]octane compound'20128,163,794'Crystalline form of a 3-phenoxymethylpyrrolidine compound'20128,134,006'Dialkylphenyl compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity'20128,106,232'3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists'20128,101,766'Crystalline form of a biphenyl compound'20128,101,794'Crystalline forms of a 3-carboxypropyl-aminotetralin compound'20127,943,772'Crystalline forms of an 8-azabicyclo(3.2.1)octane compound'20117,880,010'Crystalline forms of a dimethylphenyl compound'20117,687,521'Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity'20107,524,965'Dialkylphenyl compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity'20097,521,558'Crystalline form of a biphenyl compound'20097,320,990'Crystalline form of a biphenyl compound'2008

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2008–2014Patents assigned to THERAVANCE INC (22)· patent assignee history
2008–2014Based in Sunnyvale, CA, US· patent location history
2012–2017Patents assigned to RAPTA MIROSLAV (27)· patent assignee history
2012–2016Patents assigned to COLSON PIERRE-JEAN (11)· patent assignee history
2012–2021Based in San Carlos, CA, US· patent location history
2014–2015Patents assigned to THERAVANCE BIOPHARMA R & D IP LLC (9)· patent assignee history
2016–2021Patents assigned to THERAVANCE BIOPHARMA R&D IP LLC (24)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
RAPTA MIROSLAVself272012–2017
THERAVANCE BIOPHARMA R&D IP LLC242016–2021
THERAVANCE INC222008–2014
COLSON PIERRE-JEAN112012–2016
THERAVANCE BIOPHARMA R & D IP LLC92014–2015
Locations
LocationPatentsSpan
San Carlos, California, US422012–2021
Sunnyvale, California, US132008–2014